Analgesics Market By Type (Non opioids, Opioids), By Route of Administration (Oral, Intravenous, Rectal, Transdermal, Topical): Global Opportunity Analysis and Industry Forecast, 2020-2030
The global analgesics market was valued at $26,654.4 million in 2020, and is projected to reach $50,682.6 million by 2030, registering a CAGR of 6.6% during the forecast period 2021-2030. Analgesics, also known as painkillers, are used to treat and reduce pain in the body. Typically, they are used when the pain is severe and becomes unbearable for the patient. Non-opioids, opioids, and compound analgesics (a combination of both, opioids and non-opioids) are the major analgesic products used globally. The emergence of painkillers is mainly attributed to the increase in acute and chronic diseases, as well as the rise in incidences of cancer globally.
Opioid drugs are the strongest types of painkillers, which are derived from opium. They are chiefly used for the treatment of moderate to severe pain and are mostly available through prescription. On the other hand, non-opioid drugs are not derived from opium but include acetaminophen. They also include non-steroidal anti-inflammatory drugs (NSAIDs) and are majorly used for the treatment of mild to moderate pain. In addition, non-opioid drugs are sometimes used alongside stronger painkillers. They are mostly available over-the-counter (OTC); however, some NSAIDs, such as Celebrex, Cataflam, and Motrin, are available through prescription only.
The global analgesics market is expected to achieve moderate growth in the near future, majorly because of factors, such as increase in cardiovascular disease, cancer, and arthritis and surge in geriatric population. Recurring pain and aches experienced by the ageing population is another factor drives the market growth. In addition, increase in investments in R&D by public and private sectors, with key emphasis on the classes of compounds for formulating new therapeutics, is further expected to drive the analgesics market growth. However, factors such as uncontrolled prescription of opioids, drug abuse, and unregulated government policies are expected to restrain the growth of the global analgesics market.
The analgesics market is segmented on the basis of type, route of administration, and geography. On the basis of type, the market is segmented into non-opioids and opioids. By route of administration, it is segmented into oral, intravenous, rectal, transdermal, and topical. Region-wise, it is categorized into North America, Europe, Asia-Pacific, and LAMEA.
A comprehensive competitive analysis and profiles of major market players, such as Bayer AG, Novartis AG, GlaxoSmithKline PLC, Pfizer Inc., Johnson & Johnson, Reckitt Benckiser (RB), Endo Pharmaceuticals, Bristol-Myers Squibb, Eli Lilly and Company, and Sanofi, are provided in this report.
KEY BENEFITS FOR STAKEHOLDERS
This report provides a detailed quantitative analysis of the current market trends and future estimations from 2021 to 2030, which assists to identify the prevailing market opportunities.
An in-depth analysis of various regions is anticipated to provide a detailed understanding of the current trends to enable stakeholders to formulate region-specific plans.
A comprehensive analysis of the factors that drive and restrain the growth of the analgesics market is provided.
An extensive analysis of various regions provides insights that allow companies to strategically plan their business moves.
Key market players and their strategies have been analyzed to understand the competitive outlook of the market.
Key Market Segments
By Type
Non opioids
Opioids
By Route of Administration
Rectal
Transdermal
Topical
Oral
Intravenous
By Region
North America
U.S.
Canada
Mexico
Europe
United Kingdom
Germany
Spain
Sweden
France
Russia
Denmark
Rest of Europe
Asia-Pacific
Japan
China
India
Australia
Indonesia
Rest of Asia-Pacific
LAMEA
Saudi Arabia
UAE
Morocco
Kenya
Nigeria
Brazil
Venezuela
Chile
Rest of LAMEA
Key Market Players
Abbott Laboratories
AbbVie Inc.
Bayer AG
Eli Lilly and Company
endo pharmaceuticals
Glaxosmithkline plc
johnson and johnson md&d
Pfizer, Inc.
Reckitt Benckiser Group
Sanofi
- CHAPTER 1:INTRODUCTION
- 1.1.Report description
- 1.2.Key market segments
- 1.3.Key benefits to the stakeholders
- 1.4.Research Methodology
- 1.4.1.Secondary research
- 1.4.2.Primary research
- 1.4.3.Analyst tools and models
- CHAPTER 2:EXECUTIVE SUMMARY
- 2.1.Key findings of the study
- 2.2.CXO Perspective
- CHAPTER 3:MARKET OVERVIEW
- 3.1.Market definition and scope
- 3.2.Key findings
- 3.2.1.Top investment pockets
- 3.3.Porter’s five forces analysis
- 3.4.Top player positioning
- 3.5.Market dynamics
- 3.5.1.Drivers
- 3.5.2.Restraints
- 3.5.3.Opportunities
- 3.6.COVID-19 Impact Analysis on the market
- CHAPTER 4: ANALGESICS MARKET, BY TYPE
- 4.1 Overview
- 4.1.1 Market size and forecast
- 4.2 Non opioids
- 4.2.1 Key market trends, growth factors and opportunities
- 4.2.2 Market size and forecast, by region
- 4.2.3 Market analysis by country
- 4.3 Opioids
- 4.3.1 Key market trends, growth factors and opportunities
- 4.3.2 Market size and forecast, by region
- 4.3.3 Market analysis by country
- CHAPTER 5: ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION
- 5.1 Overview
- 5.1.1 Market size and forecast
- 5.2 Oral
- 5.2.1 Key market trends, growth factors and opportunities
- 5.2.2 Market size and forecast, by region
- 5.2.3 Market analysis by country
- 5.3 Intravenous
- 5.3.1 Key market trends, growth factors and opportunities
- 5.3.2 Market size and forecast, by region
- 5.3.3 Market analysis by country
- 5.4 Rectal
- 5.4.1 Key market trends, growth factors and opportunities
- 5.4.2 Market size and forecast, by region
- 5.4.3 Market analysis by country
- 5.5 Transdermal
- 5.5.1 Key market trends, growth factors and opportunities
- 5.5.2 Market size and forecast, by region
- 5.5.3 Market analysis by country
- 5.6 Topical
- 5.6.1 Key market trends, growth factors and opportunities
- 5.6.2 Market size and forecast, by region
- 5.6.3 Market analysis by country
- CHAPTER 6: ANALGESICS MARKET, BY REGION
- 6.1 Overview
- 6.1.1 Market size and forecast
- 6.2 North America
- 6.2.1 Key trends and opportunities
- 6.2.2 North America Market size and forecast, by Type
- 6.2.3 North America Market size and forecast, by Route of Administration
- 6.2.4 North America Market size and forecast, by country
- 6.2.4.1 U.S.
- 6.2.4.1.1 Market size and forecast, by Type
- 6.2.4.1.2 Market size and forecast, by Route of Administration
- 6.2.4.2 Canada
- 6.2.4.2.1 Market size and forecast, by Type
- 6.2.4.2.2 Market size and forecast, by Route of Administration
- 6.2.4.3 Mexico
- 6.2.4.3.1 Market size and forecast, by Type
- 6.2.4.3.2 Market size and forecast, by Route of Administration
- 6.3 Europe
- 6.3.1 Key trends and opportunities
- 6.3.2 Europe Market size and forecast, by Type
- 6.3.3 Europe Market size and forecast, by Route of Administration
- 6.3.4 Europe Market size and forecast, by country
- 6.3.4.1 United Kingdom
- 6.3.4.1.1 Market size and forecast, by Type
- 6.3.4.1.2 Market size and forecast, by Route of Administration
- 6.3.4.2 Germany
- 6.3.4.2.1 Market size and forecast, by Type
- 6.3.4.2.2 Market size and forecast, by Route of Administration
- 6.3.4.3 Spain
- 6.3.4.3.1 Market size and forecast, by Type
- 6.3.4.3.2 Market size and forecast, by Route of Administration
- 6.3.4.4 Sweden
- 6.3.4.4.1 Market size and forecast, by Type
- 6.3.4.4.2 Market size and forecast, by Route of Administration
- 6.3.4.5 France
- 6.3.4.5.1 Market size and forecast, by Type
- 6.3.4.5.2 Market size and forecast, by Route of Administration
- 6.3.4.6 Russia
- 6.3.4.6.1 Market size and forecast, by Type
- 6.3.4.6.2 Market size and forecast, by Route of Administration
- 6.3.4.7 Denmark
- 6.3.4.7.1 Market size and forecast, by Type
- 6.3.4.7.2 Market size and forecast, by Route of Administration
- 6.3.4.8 Rest of Europe
- 6.3.4.8.1 Market size and forecast, by Type
- 6.3.4.8.2 Market size and forecast, by Route of Administration
- 6.4 Asia-Pacific
- 6.4.1 Key trends and opportunities
- 6.4.2 Asia-Pacific Market size and forecast, by Type
- 6.4.3 Asia-Pacific Market size and forecast, by Route of Administration
- 6.4.4 Asia-Pacific Market size and forecast, by country
- 6.4.4.1 Japan
- 6.4.4.1.1 Market size and forecast, by Type
- 6.4.4.1.2 Market size and forecast, by Route of Administration
- 6.4.4.2 China
- 6.4.4.2.1 Market size and forecast, by Type
- 6.4.4.2.2 Market size and forecast, by Route of Administration
- 6.4.4.3 India
- 6.4.4.3.1 Market size and forecast, by Type
- 6.4.4.3.2 Market size and forecast, by Route of Administration
- 6.4.4.4 Australia
- 6.4.4.4.1 Market size and forecast, by Type
- 6.4.4.4.2 Market size and forecast, by Route of Administration
- 6.4.4.5 Indonesia
- 6.4.4.5.1 Market size and forecast, by Type
- 6.4.4.5.2 Market size and forecast, by Route of Administration
- 6.4.4.6 Rest of Asia-Pacific
- 6.4.4.6.1 Market size and forecast, by Type
- 6.4.4.6.2 Market size and forecast, by Route of Administration
- 6.5 LAMEA
- 6.5.1 Key trends and opportunities
- 6.5.2 LAMEA Market size and forecast, by Type
- 6.5.3 LAMEA Market size and forecast, by Route of Administration
- 6.5.4 LAMEA Market size and forecast, by country
- 6.5.4.1 Brazil
- 6.5.4.1.1 Market size and forecast, by Type
- 6.5.4.1.2 Market size and forecast, by Route of Administration
- 6.5.4.2 Venezuela
- 6.5.4.2.1 Market size and forecast, by Type
- 6.5.4.2.2 Market size and forecast, by Route of Administration
- 6.5.4.3 Chile
- 6.5.4.3.1 Market size and forecast, by Type
- 6.5.4.3.2 Market size and forecast, by Route of Administration
- 6.5.4.4 Saudi Arabia
- 6.5.4.4.1 Market size and forecast, by Type
- 6.5.4.4.2 Market size and forecast, by Route of Administration
- 6.5.4.5 UAE
- 6.5.4.5.1 Market size and forecast, by Type
- 6.5.4.5.2 Market size and forecast, by Route of Administration
- 6.5.4.6 Morocco
- 6.5.4.6.1 Market size and forecast, by Type
- 6.5.4.6.2 Market size and forecast, by Route of Administration
- 6.5.4.7 Kenya
- 6.5.4.7.1 Market size and forecast, by Type
- 6.5.4.7.2 Market size and forecast, by Route of Administration
- 6.5.4.8 Nigeria
- 6.5.4.8.1 Market size and forecast, by Type
- 6.5.4.8.2 Market size and forecast, by Route of Administration
- 6.5.4.9 Rest of LAMEA
- 6.5.4.9.1 Market size and forecast, by Type
- 6.5.4.9.2 Market size and forecast, by Route of Administration
- CHAPTER 7: COMPANY LANDSCAPE
- 7.1. Introduction
- 7.2. Top winning strategies
- 7.3. Product Mapping of Top 10 Player
- 7.4. Competitive Dashboard
- 7.5. Competitive Heatmap
- 7.6. Key developments
- CHAPTER 8: COMPANY PROFILES
- 8.1 Abbott Laboratories
- 8.1.1 Company overview
- 8.1.2 Company snapshot
- 8.1.3 Operating business segments
- 8.1.4 Product portfolio
- 8.1.5 Business performance
- 8.1.6 Key strategic moves and developments
- 8.2 AbbVie Inc.
- 8.2.1 Company overview
- 8.2.2 Company snapshot
- 8.2.3 Operating business segments
- 8.2.4 Product portfolio
- 8.2.5 Business performance
- 8.2.6 Key strategic moves and developments
- 8.3 Bayer AG
- 8.3.1 Company overview
- 8.3.2 Company snapshot
- 8.3.3 Operating business segments
- 8.3.4 Product portfolio
- 8.3.5 Business performance
- 8.3.6 Key strategic moves and developments
- 8.4 Eli Lilly and Company
- 8.4.1 Company overview
- 8.4.2 Company snapshot
- 8.4.3 Operating business segments
- 8.4.4 Product portfolio
- 8.4.5 Business performance
- 8.4.6 Key strategic moves and developments
- 8.5 endo pharmaceuticals
- 8.5.1 Company overview
- 8.5.2 Company snapshot
- 8.5.3 Operating business segments
- 8.5.4 Product portfolio
- 8.5.5 Business performance
- 8.5.6 Key strategic moves and developments
- 8.6 Glaxosmithkline plc
- 8.6.1 Company overview
- 8.6.2 Company snapshot
- 8.6.3 Operating business segments
- 8.6.4 Product portfolio
- 8.6.5 Business performance
- 8.6.6 Key strategic moves and developments
- 8.7 johnson and johnson md&d
- 8.7.1 Company overview
- 8.7.2 Company snapshot
- 8.7.3 Operating business segments
- 8.7.4 Product portfolio
- 8.7.5 Business performance
- 8.7.6 Key strategic moves and developments
- 8.8 Pfizer, Inc.
- 8.8.1 Company overview
- 8.8.2 Company snapshot
- 8.8.3 Operating business segments
- 8.8.4 Product portfolio
- 8.8.5 Business performance
- 8.8.6 Key strategic moves and developments
- 8.9 Reckitt Benckiser Group
- 8.9.1 Company overview
- 8.9.2 Company snapshot
- 8.9.3 Operating business segments
- 8.9.4 Product portfolio
- 8.9.5 Business performance
- 8.9.6 Key strategic moves and developments
- 8.10 Sanofi
- 8.10.1 Company overview
- 8.10.2 Company snapshot
- 8.10.3 Operating business segments
- 8.10.4 Product portfolio
- 8.10.5 Business performance
- 8.10.6 Key strategic moves and developments
- LIST OF TABLES
- TABLE 1. GLOBAL ANALGESICS MARKET, BY TYPE, 2020-2030,($MILLION)
- TABLE 2. ANALGESICS MARKET REVENUE, FOR NON OPIOIDS, BY REGION , 2020-2030,($MILLION)
- TABLE 3. ANALGESICS MARKET NON OPIOIDS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 4. ANALGESICS MARKET REVENUE, FOR OPIOIDS, BY REGION , 2020-2030,($MILLION)
- TABLE 5. ANALGESICS MARKET OPIOIDS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 6. GLOBAL ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030,($MILLION)
- TABLE 7. ANALGESICS MARKET REVENUE, FOR ORAL, BY REGION , 2020-2030,($MILLION)
- TABLE 8. ANALGESICS MARKET ORAL BY COUNTRY, 2020-2030,($MILLION)
- TABLE 9. ANALGESICS MARKET REVENUE, FOR INTRAVENOUS, BY REGION , 2020-2030,($MILLION)
- TABLE 10. ANALGESICS MARKET INTRAVENOUS BY COUNTRY, 2020-2030,($MILLION)
- TABLE 11. ANALGESICS MARKET REVENUE, FOR RECTAL, BY REGION , 2020-2030,($MILLION)
- TABLE 12. ANALGESICS MARKET RECTAL BY COUNTRY, 2020-2030,($MILLION)
- TABLE 13. ANALGESICS MARKET REVENUE, FOR TRANSDERMAL, BY REGION , 2020-2030,($MILLION)
- TABLE 14. ANALGESICS MARKET TRANSDERMAL BY COUNTRY, 2020-2030,($MILLION)
- TABLE 15. ANALGESICS MARKET REVENUE, FOR TOPICAL, BY REGION , 2020-2030,($MILLION)
- TABLE 16. ANALGESICS MARKET TOPICAL BY COUNTRY, 2020-2030,($MILLION)
- TABLE 17. ANALGESICS MARKET, BY REGION, 2020-2030,($MILLION)
- TABLE 18. NORTH AMERICA ANALGESICS MARKET, BY TYPE, 2020-2030,($MILLION)
- TABLE 19. NORTH AMERICA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030,($MILLION)
- TABLE 20. NORTH AMERICA ANALGESICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 21. U.S. ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 22. U.S. ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 23. CANADA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 24. CANADA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 25. MEXICO ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 26. MEXICO ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 27. EUROPE ANALGESICS MARKET, BY TYPE, 2020-2030,($MILLION)
- TABLE 28. EUROPE ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030,($MILLION)
- TABLE 29. EUROPE ANALGESICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 30. UNITED KINGDOM ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 31. UNITED KINGDOM ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 32. GERMANY ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 33. GERMANY ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 34. SPAIN ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 35. SPAIN ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 36. SWEDEN ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 37. SWEDEN ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 38. FRANCE ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 39. FRANCE ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 40. RUSSIA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 41. RUSSIA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 42. DENMARK ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 43. DENMARK ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 44. REST OF EUROPE ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 45. REST OF EUROPE ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 46. ASIA-PACIFIC ANALGESICS MARKET, BY TYPE, 2020-2030,($MILLION)
- TABLE 47. ASIA-PACIFIC ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030,($MILLION)
- TABLE 48. ASIA-PACIFIC ANALGESICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 49. JAPAN ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 50. JAPAN ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 51. CHINA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 52. CHINA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 53. INDIA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 54. INDIA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 55. AUSTRALIA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 56. AUSTRALIA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 57. INDONESIA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 58. INDONESIA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 59. REST OF ASIA-PACIFIC ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 60. REST OF ASIA-PACIFIC ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 61. LAMEA ANALGESICS MARKET, BY TYPE, 2020-2030,($MILLION)
- TABLE 62. LAMEA ANALGESICS MARKET, BY ROUTE OF ADMINISTRATION, 2020-2030,($MILLION)
- TABLE 63. LAMEA ANALGESICS MARKET, BY COUNTRY, 2020-2030,($MILLION)
- TABLE 64. BRAZIL ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 65. BRAZIL ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 66. VENEZUELA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 67. VENEZUELA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 68. CHILE ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 69. CHILE ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 70. SAUDI ARABIA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 71. SAUDI ARABIA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 72. UAE ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 73. UAE ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 74. MOROCCO ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 75. MOROCCO ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 76. KENYA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 77. KENYA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 78. NIGERIA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 79. NIGERIA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 80. REST OF LAMEA ANALGESICS MARKET BY TYPE 2020-2030,($MILLION)
- TABLE 81. REST OF LAMEA ANALGESICS MARKET BY ROUTE OF ADMINISTRATION 2020-2030,($MILLION)
- TABLE 82.ABBOTT LABORATORIES: COMPANY SNAPSHOT
- TABLE 83.ABBOTT LABORATORIES: OPERATING SEGMENTS
- TABLE 84.ABBOTT LABORATORIES: PRODUCT PORTFOLIO
- TABLE 85.ABBOTT LABORATORIES: NET SALES,
- TABLE 86.ABBOTT LABORATORIES: KEY STRATERGIES
- TABLE 87.ABBVIE INC.: COMPANY SNAPSHOT
- TABLE 88.ABBVIE INC.: OPERATING SEGMENTS
- TABLE 89.ABBVIE INC.: PRODUCT PORTFOLIO
- TABLE 90.ABBVIE INC.: NET SALES,
- TABLE 91.ABBVIE INC.: KEY STRATERGIES
- TABLE 92.BAYER AG: COMPANY SNAPSHOT
- TABLE 93.BAYER AG: OPERATING SEGMENTS
- TABLE 94.BAYER AG: PRODUCT PORTFOLIO
- TABLE 95.BAYER AG: NET SALES,
- TABLE 96.BAYER AG: KEY STRATERGIES
- TABLE 97.ELI LILLY AND COMPANY: COMPANY SNAPSHOT
- TABLE 98.ELI LILLY AND COMPANY: OPERATING SEGMENTS
- TABLE 99.ELI LILLY AND COMPANY: PRODUCT PORTFOLIO
- TABLE 100.ELI LILLY AND COMPANY: NET SALES,
- TABLE 101.ELI LILLY AND COMPANY: KEY STRATERGIES
- TABLE 102.ENDO PHARMACEUTICALS: COMPANY SNAPSHOT
- TABLE 103.ENDO PHARMACEUTICALS: OPERATING SEGMENTS
- TABLE 104.ENDO PHARMACEUTICALS: PRODUCT PORTFOLIO
- TABLE 105.ENDO PHARMACEUTICALS: NET SALES,
- TABLE 106.ENDO PHARMACEUTICALS: KEY STRATERGIES
- TABLE 107.GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
- TABLE 108.GLAXOSMITHKLINE PLC: OPERATING SEGMENTS
- TABLE 109.GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
- TABLE 110.GLAXOSMITHKLINE PLC: NET SALES,
- TABLE 111.GLAXOSMITHKLINE PLC: KEY STRATERGIES
- TABLE 112.JOHNSON AND JOHNSON MD&D: COMPANY SNAPSHOT
- TABLE 113.JOHNSON AND JOHNSON MD&D: OPERATING SEGMENTS
- TABLE 114.JOHNSON AND JOHNSON MD&D: PRODUCT PORTFOLIO
- TABLE 115.JOHNSON AND JOHNSON MD&D: NET SALES,
- TABLE 116.JOHNSON AND JOHNSON MD&D: KEY STRATERGIES
- TABLE 117.PFIZER, INC.: COMPANY SNAPSHOT
- TABLE 118.PFIZER, INC.: OPERATING SEGMENTS
- TABLE 119.PFIZER, INC.: PRODUCT PORTFOLIO
- TABLE 120.PFIZER, INC.: NET SALES,
- TABLE 121.PFIZER, INC.: KEY STRATERGIES
- TABLE 122.RECKITT BENCKISER GROUP: COMPANY SNAPSHOT
- TABLE 123.RECKITT BENCKISER GROUP: OPERATING SEGMENTS
- TABLE 124.RECKITT BENCKISER GROUP: PRODUCT PORTFOLIO
- TABLE 125.RECKITT BENCKISER GROUP: NET SALES,
- TABLE 126.RECKITT BENCKISER GROUP: KEY STRATERGIES
- TABLE 127.SANOFI: COMPANY SNAPSHOT
- TABLE 128.SANOFI: OPERATING SEGMENTS
- TABLE 129.SANOFI: PRODUCT PORTFOLIO
- TABLE 130.SANOFI: NET SALES,
- TABLE 131.SANOFI: KEY STRATERGIES
- LIST OF FIGURES
- FIGURE 1.ANALGESICS MARKET SEGMENTATION
- FIGURE 2.ANALGESICS MARKET,2020-2030
- FIGURE 3.ANALGESICS MARKET,2020-2030
- FIGURE 4. TOP INVESTMENT POCKETS, BY REGION
- FIGURE 5.PORTER FIVE-1
- FIGURE 6.PORTER FIVE-2
- FIGURE 7.PORTER FIVE-3
- FIGURE 8.PORTER FIVE-4
- FIGURE 9.PORTER FIVE-5
- FIGURE 10.TOP PLAYER POSITIONING
- FIGURE 11.ANALGESICS MARKET:DRIVERS, RESTRAINTS AND OPPORTUNITIES
- FIGURE 12.ANALGESICS MARKET,BY TYPE,2020(%)
- FIGURE 13.COMPARATIVE SHARE ANALYSIS OF NON OPIOIDS ANALGESICS MARKET,2020-2030(%)
- FIGURE 14.COMPARATIVE SHARE ANALYSIS OF OPIOIDS ANALGESICS MARKET,2020-2030(%)
- FIGURE 15.ANALGESICS MARKET,BY ROUTE OF ADMINISTRATION,2020(%)
- FIGURE 16.COMPARATIVE SHARE ANALYSIS OF ORAL ANALGESICS MARKET,2020-2030(%)
- FIGURE 17.COMPARATIVE SHARE ANALYSIS OF INTRAVENOUS ANALGESICS MARKET,2020-2030(%)
- FIGURE 18.COMPARATIVE SHARE ANALYSIS OF RECTAL ANALGESICS MARKET,2020-2030(%)
- FIGURE 19.COMPARATIVE SHARE ANALYSIS OF TRANSDERMAL ANALGESICS MARKET,2020-2030(%)
- FIGURE 20.COMPARATIVE SHARE ANALYSIS OF TOPICAL ANALGESICS MARKET,2020-2030(%)
- FIGURE 21.ANALGESICS MARKET BY REGION,2020
- FIGURE 22.U.S. ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 23.CANADA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 24.MEXICO ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 25.UNITED KINGDOM ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 26.GERMANY ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 27.SPAIN ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 28.SWEDEN ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 29.FRANCE ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 30.RUSSIA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 31.DENMARK ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 32.REST OF EUROPE ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 33.JAPAN ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 34.CHINA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 35.INDIA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 36.AUSTRALIA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 37.INDONESIA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 38.REST OF ASIA-PACIFIC ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 39.BRAZIL ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 40.VENEZUELA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 41.CHILE ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 42.SAUDI ARABIA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 43.UAE ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 44.MOROCCO ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 45.KENYA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 46.NIGERIA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 47.REST OF LAMEA ANALGESICS MARKET,2020-2030($MILLION)
- FIGURE 48. TOP WINNING STRATEGIES, BY YEAR
- FIGURE 49. TOP WINNING STRATEGIES, BY DEVELOPMENT
- FIGURE 50. TOP WINNING STRATEGIES, BY COMPANY
- FIGURE 51.PRODUCT MAPPING OF TOP 10 PLAYERS
- FIGURE 52.COMPETITIVE DASHBOARD
- FIGURE 53.COMPETITIVE HEATMAP OF TOP 10 KEY PLAYERS
- FIGURE 54.ABBOTT LABORATORIES.: NET SALES ,($MILLION)
- FIGURE 55.ABBVIE INC..: NET SALES ,($MILLION)
- FIGURE 56.BAYER AG.: NET SALES ,($MILLION)
- FIGURE 57.ELI LILLY AND COMPANY.: NET SALES ,($MILLION)
- FIGURE 58.ENDO PHARMACEUTICALS.: NET SALES ,($MILLION)
- FIGURE 59.GLAXOSMITHKLINE PLC.: NET SALES ,($MILLION)
- FIGURE 60.JOHNSON AND JOHNSON MD&D.: NET SALES ,($MILLION)
- FIGURE 61.PFIZER, INC..: NET SALES ,($MILLION)
- FIGURE 62.RECKITT BENCKISER GROUP.: NET SALES ,($MILLION)
- FIGURE 63.SANOFI.: NET SALES ,($MILLION)
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook